It is a cancer immunotherapy that processes cancer cells and immune cells, which become unnecessary with ascites treatment CART (ascites filtration concentration reinfusion method), and then returns them to the patient's body.
"Shin Beck" is a cancer immunotherapy that processes the patient's own cells collected through CART (ascites treatment) and then administers them to the patient to activate immune cells in the body. It is possible to administer the treatment to the patient within a short period (about one week) after receiving the CART waste bag. The activated immune cells (NK and killer T cells) in the body kill tumor cells. [Features] - Activates immune cells in the body - Immune cells (NK and killer T cells) kill tumor cells - Can be administered to the patient within a short period (about one week) *For more details, please refer to the PDF materials or feel free to contact us.
Inquire About This Product
basic information
For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
For more details, please refer to the PDF document or feel free to contact us.
catalog（1）
Download All Catalogs
Company information
At Accelvex, we provide advanced medical support such as therapeutic cell processing. In recent years, the progress in cancer immunotherapy has been remarkable, with an increasing number of new approaches to control the immune function in the body using molecular targeted therapies like antibody drugs and checkpoint inhibitors. The self-tumor cell vector "SynVC," developed with our technology, can present all the cancer antigens possessed by the patient's own cancer cells and tissues to the immune cells in the patient's body, allowing for the acquisition and memory of immunity specific to cancer antigens.
!["Composite catalysts" that assist in the efficient synthesis of high value-added substances [Shinshu University]](https://image.www.ipros.com/public/product/image/565/2000699938/IPROS91537967205258017617.png?w=280&h=280)
